Pakistan Society of Neuro-Oncology

Ivy Brain Tumor Center Announces Promising Data for Niraparib in Phase 0/2 Glioblastoma Clinical Trial

Retrieved on: 
Friday, November 17, 2023
Temozolomide, Glomus tumor, Barrow Neurological Institute, Brain, Safety, Annual general meeting, PST, Progression-free survival, Glioblastoma, Clinical trial, Patient, Thrombocytopenia, PFS, Radiation, Pakistan Society of Neuro-Oncology, GSK, PARP, Standard of care, MGMT, Niraparib, Survival, Society, SNO, HIV disease progression rates, Hedera, Pharmaceutical industry, Medical imaging, Oncology

Phoenix, AZ, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a Phase 0/2 trial of niraparib in patients with newly diagnosed glioblastoma with unmethylated MGMT.

Key Points: 
  • Phoenix, AZ, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a Phase 0/2 trial of niraparib in patients with newly diagnosed glioblastoma with unmethylated MGMT.
  • Glioblastoma is an incurable malignant brain tumor and MGMT-unmethylated glioblastoma is the most common and fastest-recurring variant, comprising more than 60 percent of all glioblastoma tumors.
  • In the Phase 0 component of the study, patients exposed to niraparib demonstrated high drug concentrations in brain tumor tissue.
  • These presentations represent a broader portfolio of pharmacodynamic and pharmacokinetic-driven clinical trials, utilizing industry-supported drug development to test new-in-class therapies for brain tumor patients.

Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology

Retrieved on: 
Friday, November 17, 2023
Annual general meeting, Hope, Medical director, University of Pennsylvania, Toxin, Glioblastoma, Neurology, Patient, ECA, Radiation, MDNA, Pakistan Society of Neuro-Oncology, Convection, University, Survival, Administration, IL4R, Recurrence, TSX, Poster, OTC, Decompression (diving), Society, SNO, Pharmaceutical industry

TORONTO and HOUSTON, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and an oral summary highlighting longer term follow up results from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company’s first-in-class IL-4R targeted therapy for the treatment of patients with recurrent glioblastoma (rGBM), will be presented by Dr. Steven Brem, M.D. (Medical Director, Centre for Precision Surgery, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania) at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada.

Key Points: 
  • “Bizaxofusp represents an exciting new approach by demonstrating a dose-dependent effect on the receptor of IL-4, an immuno-suppressive cytokine.
  • The data offers new hope for patients with glioblastoma who have few treatment options at recurrence,” said Dr. Steven Brem.
  • The data demonstrated that a single treatment with bizaxofusp increased median overall survival (mOS) by 72% compared to the ECA (12.4 months vs. 7.2 months).
  • Overall survival (OS) for bizaxofusp-treated patients increased 370% at Year 1 and increased more than 50% at Year 2.

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Retrieved on: 
Friday, November 17, 2023
Research, Annual general meeting, Food, Pakistan Society of Neuro-Oncology, Head, Patient, FDA, BRAF, Abstract, MD, Doctor of Philosophy, SNO, Pharmaceutical industry, Nature Medicine

Subsets of the data will also be presented today in two oral plenary presentations at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting in Vancouver, Canada.

Key Points: 
  • Subsets of the data will also be presented today in two oral plenary presentations at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting in Vancouver, Canada.
  • “The study results published in Nature Medicine demonstrate promising evidence with respect to the the impact of tovorafenib for children and young adults with BRAF-altered relapsed or progressive pLGG, a debilitating form of brain tumor that currently has no approved systemic therapies,” said Dr. Samuel Blackman, co-founder and head of research and development, Day One.
  • A New Drug Application for tovorafenib monotherapy in BRAF-altered relapsed or progressive pLGG is currently under priority review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act target action date of April 30, 2024.
  • In addition to FIREFLY-1, the Phase 3 FIREFLY-2/LOGGIC randomized clinical trial is evaluating tovorafenib frontline therapy for patients newly diagnosed with pLGG.

Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

Retrieved on: 
Tuesday, November 14, 2023
Doctor of Philosophy, Bispecific monoclonal antibody, Pancreatic cancer, MSI, Brain, Research, Annual general meeting, Glioblastoma, Metalloproteinase, Toronto Stock Exchange, Patient, MDNA, Pakistan Society of Neuro-Oncology, Intellectual property, Pembrolizumab, OTC Markets Group, Neuro-Oncology (journal), Conference, Standard of care, Melanoma, SITC, Survival, Partnership, Cancer, Neoplasm, Bifunctional, TSX, SNO, Microsatellite instability, Decompression (diving), Society, MMR, Patent, Pharmaceutical industry, Cryptocurrency, Immunotherapy

TORONTO and HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA; OTC: MDNAF), a clinical-stage company focused on the design and development of novel evolutionary superkines to create revolutionary immunotherapies, today announced financial results and corporate highlights for the second quarter of fiscal 2024, ended September 30, 2023.

Key Points: 
  • We look forward to reporting initial Phase 2 dose expansion data from both the monotherapy and combination arms during the first half of 2024,” concluded Dr.
  • Clinical update from the ABILITY study’s MDNA11 plus pembrolizumab Phase 2 combination arm expected in the first half of 2024.
  • Research and development expenses of $3.1 million were incurred during the quarter ended September 30, 2023, compared with $2.4 million incurred in the quarter ended September 30, 2022.
  • General and administrative expenses of $2.3 million were incurred during the quarter ended September 30, 2023, compared with $2.4 million during the quarter ended September 30, 2022.

Enterome to Present Updated Data From Phase 1/2 ROSALIE Trial of its Peptide-Based Immunotherapy EO2401 in Recurrent Glioblastoma at SNO 2023

Retrieved on: 
Monday, November 13, 2023
Dana–Farber Cancer Institute, Bevacizumab, Glioblastoma, Patient, Inflammation, Pakistan Society of Neuro-Oncology, Neuro-Oncology (journal), Harvard Medical School, Nivolumab, Immunotherapy, Society, SNO, Official Journal, Pharmaceutical industry, Medicine

PARIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced it will present updated efficacy data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in patients with first progression/recurrence of glioblastoma (the EOGBM1-18/ROSALIE study), in an oral presentation at the Society for Neuro-Oncology (SNO) 28th Annual Meeting which will be held in Vancouver, British Columbia, Canada on November 15-19, 2023.

Key Points: 
  • PARIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced it will present updated efficacy data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in patients with first progression/recurrence of glioblastoma (the EOGBM1-18/ROSALIE study), in an oral presentation at the Society for Neuro-Oncology (SNO) 28th Annual Meeting which will be held in Vancouver, British Columbia, Canada on November 15-19, 2023.
  • Title: EO2401 peptide immunotherapy + nivolumab +/- bevacizumab in first recurrent glioblastoma: the phase 1/2 EOGBM1-18/ROSALIE study (NCT04116658)
    Presenting Author: Prof. David Reardon, M.D., Professor of Medicine at Harvard Medical School, and Clinical Director for Dana Farber Cancer Institute
    Link to abstract published in a supplement to Neuro-Oncology, the Official Journal of the Society for Neuro-Oncology, can be found here .
  • The slides from the oral presentation will be available on Enterome’s website after the Meeting.

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

Retrieved on: 
Monday, November 13, 2023
Therapy, Glioblastoma, MTA, GBM, Patient, Pakistan Society of Neuro-Oncology, PRMT5, Neuro-Oncology (journal), Abstract, Nervous tissue, SNO, Society, Pharmaceutical industry, MPNST

BOSTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that two abstracts have been selected for poster presentations at the Society for Neuro-Oncology (SNO) 28th Annual Meeting taking place November 15-19, 2023, in Vancouver, Canada.

Key Points: 
  • “TNG908 demonstrates strong antitumor activity in MTAP-deleted glioblastoma models.
  • Additionally, data from preclinical malignant peripheral nerve sheath tumor models evaluating TNG908 and TNG462 demonstrate efficacy at well-tolerated doses.
  • The clinical stage MTA-cooperative PRMT5 inhibitors TNG908 and TNG462 are efficacious in MPNST preclinical models and represent potential new therapeutic strategies for patients with MTAP-deleted MPNST.
  • Abstract titles, presentation information and text are currently available to the public in the 2023 abstract supplement to SNO’s official journal, Neuro-Oncology.

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

Retrieved on: 
Friday, November 10, 2023
Arm, Safety, Progression-free survival, ODD, TTP, Disease, GBM, Patient, Cleveland Clinic, PFS, Pakistan Society of Neuro-Oncology, FDA, Immunotherapy, Glioblastoma, ORR, University, MD, Cancer, Tips, Society, SNO, Autotransplantation, DRI, Pharmaceutical industry

NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that the Company will present two posters at the Society for Neuro-Oncology (SNO) 28th Annual Meeting, taking place November 15-19, 2023, in Vancouver, British Columbia. The posters highlight the potential of IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI), genetically modified and chemotherapy-resistant gamma-delta T cells to treat patients with newly diagnosed glioblastoma multiforme (GBM). The first poster is a TIPs poster detailing the study design for INB-400, the company-sponsored Phase 2 trial and the second will be a “late-breaker” poster providing updated clinical data from the Phase 1 INB-200 trial.

Key Points: 
  • The posters highlight the potential of IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI), genetically modified and chemotherapy-resistant gamma-delta T cells to treat patients with newly diagnosed glioblastoma multiforme (GBM).
  • “We are encouraged by the safety and preliminary efficacy signal we have seen in our Phase 1 trial treating GBM patients with autologous, genetically modified gamma-delta T cells.
  • The University of Louisville and The Cleveland Clinic are the first clinical sites activated to enroll patients.
  • GBM remains a disease with significant unmet need, with limited treatment options and poor associated outcomes.

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Johns Hopkins University, Deltex Medical Group, Annual general meeting, Pakistan Society of Neuro-Oncology, Progression-free survival, University, HSCT, ASH, Cohort, Glioblastoma, TTP, IND, GBM, Leukemia, Patient, Research and development, Abstract, Cleveland Clinic, PFS, Research, Immunotherapy, CRS, IPSC, ORR, CD33, Ovarian cancer, Cancer, Development, CML, Survival, Bone marrow, SITC, Arms, AML, Gamma delta T cell, Society, SNO, CD123, Poster, KOL, University of Chicago, DRI, Pharmaceutical industry, Medical imaging

Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.

Key Points: 
  • Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results, operational highlights and recent corporate developments for the third quarter ended September 30, 2023.
  • The presentation at ASH will highlight clinical data updating the efficacy results of INB-100 including complete responses (CRs) and durability.
  • Cash: As of September 30, 2023, the Company had cash of $12.9 million, compared to $17.0 million as of June 30, 2023.

SonALAsense Presents Preliminary Data From Clinical Study in Patients With Deadly Pediatric Brain Tumor

Retrieved on: 
Wednesday, December 13, 2023
Surgery, Medical Devices, Neurology, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Oncology, SDT, Radiation, Hope, Pakistan Society of Neuro-Oncology, Sonodynamic therapy, Patient, Aminolevulinic acid, Death, Diffusion, Steroid, Incisionless Fritsch otoplasty, Neurosurgery, Hydrogen chloride, Diagnosis, Survival, Diffuse intrinsic pontine glioma, Infrared spectroscopy correlation table, Quality of life, DIPG, SNO, Metastasis, Medical imaging, Pharmaceutical industry, Development

These results were presented at the November 2023 Society for Neuro-Oncology (SNO) Annual Meeting in Vancouver, Canada.

Key Points: 
  • These results were presented at the November 2023 Society for Neuro-Oncology (SNO) Annual Meeting in Vancouver, Canada.
  • The preliminary data from Study SDT-201 shows signals of clinical activity and no safety concerns.
  • Study SDT-201 is a dose escalation and expansion study in patients with DIPG.
  • Six (6) patients have been treated to date and dose escalation is ongoing.

BioMimetix Presents Data from Phase 2 Study of BMX-001 Demonstrating Increased Survival of 6.6 Months in High Grade Glioma Patients at the 2023 Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Friday, November 17, 2023
Oncology, Health, Neurology, Clinical Trials, Research, Science, Biotechnology, Temozolomide, Annual general meeting, Radiation, Porphyrin, Pakistan Society of Neuro-Oncology, HGG, Disease, Patient, TMZ, White matter, Neuro-Oncology (journal), Prognosis, Standard of care, MD, RT, Cancer, Survival, Toxic leukoencephalopathy, Growth, Neoplasm, Quality of life, SNO, Lead, Medical imaging, Cognition

“Patients with high grade glioma are challenging to treat because the disease grows quickly, ultimately outcomes are very poor for these patients and often carries an unfavorable prognosis.

Key Points: 
  • “Patients with high grade glioma are challenging to treat because the disease grows quickly, ultimately outcomes are very poor for these patients and often carries an unfavorable prognosis.
  • This is demonstrated by the promising effects seen in this trial with BMX-001 on patients with high grade glioma receiving concurrent radiation and chemotherapies,” said James Crapo, M.D., Chief Executive Officer at BioMimetix.
  • “High grade glioma is an aggressive brain cancer with a low survival rate that affects 10,000-15,000 people in the US per year.
  • Patients on concurrent RT/TMZ who also received BMX-001 were found to have an increased median survival of 6.6 months.